<DOC>
	<DOCNO>NCT02238977</DOCNO>
	<brief_summary>The propose study evaluate response remission rate major depressive disorder ( MDD ) end-stage renal disease ( ESRD ) patient undergo maintenance hemodialysis ( HD ) treat bupropion fluoxetine 12 week . In addition , study document relative tolerability safety , longitudinally contrast effect bupropion fluoxetine measure cognitive function , fatigue , inflammation , tryptophan ( TRP ) TRP catabolites blood . It hypothesize drug significantly reduce MDD symptom baseline , tolerable safe , bupropion associate great reduction pro-inflammatory cytokine , cognitive impairment , fatigue compare fluoxetine . The Specific Aims study : Aim 1 : Determine efficacy bupropion fluoxetine treatment MDD ESRD/HD patient . Aim 2 : Determine whether longitudinal change MDD symptom , cognitive dysfunction , fatigue differ bupropion fluoxetine . Aim 3 : Determine whether longitudinal change MDD symptom , cognitive dysfunction , fatigue correlate change inflammation , measure TRP availability brain , neurotoxic TRP metabolite . Hypotheses : 1 . Bupropion fluoxetine show efficacy treat MDD ; 2 . Bupropion lead great improvement cognitive dysfunction fatigue fluoxetine ; 3 . Change cognition fatigue time correlate change c-reactive protein ( CRP ) quinolinic acid change overall depression score correlate measure TRP availability .</brief_summary>
	<brief_title>Bupropion Depression ESRD Patients Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>age 3070 yr ; patent noninfected arteriovenous fistula graft ; receive maintenance HD 3 time per week last 34 hour ; serum albumin ≥ 3.2 g/dl , serum phosphate &lt; 6.5 mg/dl , serum hemoglobin ≥9 mg/dl consecutive two blood test per National Kidney Foundation Disease Outcomes Quality Initiative ( NKF KDOQI ) guideline [ subject fail screen due blood test allow rescreened 30 day ] ; receive stable maintenance dose iron erythropoietinstimulating agent , statin , angiotension receptor blocker and/or angiotension convert enzyme inhibitor , phosphate binder , vitamin D receptor analog agent may influence cytokine propose study ; meet Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) criteria MDD ; HamD score &gt; 17 meet DSMIV criterion Bipolar Disorder psychotic disorder month prior screen ; take antidepressant , antianxiety medication , hypnotic ( include Zyban smoke cessation ) ; fail respond tolerate bupropion fluoxetine past allergic fluoxetine bupropion know history HIV/AIDS ; No test conduct screening purpose know history alcohol drug abuse dependence within month prior screen base clinical record ; history myocardial infarction heart failure within one month screen history seizure stroke point ; history chronic liver disease diagnosis hepatic encephalopathy base clinical record ; currently diagnose cancer receive cancer treatment ; history infection within last 2 week ; currently take antibiotic , antiinflammatory , immunemodulator agent ; record noncompliance dialysis schedule ; currently participate clinical behavioral intervention study . record noncompliance dialysis schedule ; currently participate clinical behavioral intervention study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>ESRD</keyword>
	<keyword>hemodialysis</keyword>
</DOC>